Larimar announced that it will provide a nomlabofusp development program update in mid-December 2024 that will include available safety, PK and frataxin data, as well as available clinical outcomes observations from patients currently receiving a daily 25 mg dose of nomlabofusp for approximately 30 to 180 days in the OLE study. An update on enrollment in the OLE study will also be provided.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics initiated with an Outperform at Oppenheimer
- Larimar Therapeutics initiated with an Outperform at Wedbush
- Wedbush bullish on Larimar Therapeutics, initiates with an Outperform
- Larimar Therapeutics initiated with a Buy at H.C. Wainwright
- Larimar Therapeutics initiated with a Buy at JonesResearch